- 著者
-
Nobuhiro Murata
Yasuo Okumura
Katsuaki Yokoyama
Naoya Matsumoto
Eizo Tachibana
Keiichiro Kuronuma
Koji Oiwa
Michiaki Matsumoto
Toshiaki Kojima
Shoji Hanada
Kazumiki Nomoto
Ken Arima
Fumiyuki Takahashi
Tomobumi Kotani
Yukitoshi Ikeya
Seiji Fukushima
Satoru Itoh
Kunio Kondo
Masaaki Chiku
Yasumi Ohno
Motoyuki Onikura
Atsushi Hirayama
for the SAKURA AF Registry Investigators
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- vol.83, no.4, pp.727-735, 2019-03-25 (Released:2019-03-25)
- 参考文献数
- 27
- 被引用文献数
-
61
Background: Off-label dosing of direct oral anticoagulants (DOACs) is encountered clinically among patients with atrial fibrillation (AF), although data on the clinical outcomes of over- and under-dosing are lacking in Japan. Methods and Results: We examined the clinical outcomes of off-label DOAC dosing using the SAKURA AF Registry, a prospective multicenter registry in Japan. Among 3,237 enrollees, 1,676 under any of the 4 DOAC regimens were followed up for a median of 39.3 months: 746 (45.0%), appropriate standard-dose; 477 (28.7%), appropriate low-dose; 66 (4.0%), over-dose; and 369 (22.2%) under-dose. Compared with the standard-dose group, patients in the under- and over-dose groups were significantly older and had a higher stroke risk. After multivariate adjustment, stroke/systemic embolism (SE) and death events were equivalent between the standard- and under-dose groups, but major bleeding events tended to be lower in the under-dose group (hazard ratio [HR] 0.474, P=0.0739). Composite events (stroke/SE, major bleeding, or death) were higher in the over-dose than in the standard-dose group (HR 2.714, P=0.0081). Conclusions: Clinical outcomes were not worse for under-dose than for standard-dose users among patients with different backgrounds. Over-dose users, however, were at higher risk for all clinical events and required careful follow-up. Further studies are needed to clarify the safety and effectiveness of off-label DOAC dosing in Japan.